SEARCH

SEARCH BY CITATION

References

  • ABAD, C., MARTINEZ, C., LECETA, J., JUARRANZ, M.G., DELGADO, M. & GOMARIZ, R.P. (2002). Pituitary adenylate cyclase-activating polypeptide expression in the immune system. Neuroimmunomodulation, 10, 177186.
  • BONKHOFF, H., STEIN, U. & REMBERGER, K. (1995). Endocrine–paracrine cell types in the prostate and prostatic adenocarcinoma are postmitotic cells. Hum. Pathol., 26, 167170.
  • BUDIHARDJO, I., OLIVER, H., LUTTER, M., LUO, X. & WANG, X. (1999). Biochemical pathways of caspase activation during apoptosis. Annu. Rev. Cell Dev. Biol., 15, 269290.
  • CARMENA, M.J. & PRIETO, J.C. (1983). Cyclic AMP-stimulating effect of vasoactive intestinal peptide in isolated epithelial cells of rat ventral prostate. Biochim. Biophys. Acta, 463, 414418.
  • DENMEADE, S.R., LIN, X.S. & ISAACS, J.T. (1996). Role of programmed (apoptotic) cell death during the progression and therapy for prostate cancer. Prostate, 28, 251265.
  • GARCÍA-FERNÁNDEZ, M.O., BODEGA, G., SOLANO, R.M., RUÍZVILLAESPESA, A., SÁNCHEZ-CHAPADO, M., CARMENA, M.J. & PRIETO, J.C. (2002). Expression and distribution of pituitary adenylate cyclase-activating polypeptide in human prostate and prostate cancer tissues. Regul. Pept., 110, 915.
  • GKONOS, P.J., GUO, F. & BURNSTEIN, K.L. (2000). Type I vasoactive intestinal peptide receptor expression in PC3/AR cells is evidence of prostate epithelial differentiation. Prostate, 42, 137144.
  • GKONOS, P.J., KRONGRAD, A. & ROOS, B.A. (1995). Neuroendocrine peptides in the prostate. Urol. Res., 23, 8187.
  • GOURLET, P., DE NEEF, P., CNUDDE, J., WAELBROECK, M. & ROBBERECHT, P. (1997a). In vitro properties of a high affinity selective antagonist of the VIP1 receptor. Peptides, 18, 15551560.
  • GOURLET, P., VANDERMEERS, A., ROBBERECHT, P. & DESCHODT-LANCKMAN, M. (1997b). Vasoactive intestinal peptide (VIP) and pituitary adenylate cyclase-activating peptide (PACAP-27, but not PACAP-38) degradation by the neutral endopeptidase EC 3.4.24.11. Biochem. Pharmacol., 54, 509515.
  • GOURLET, P., VANDERMEERS, A., VERTONGEN, P., RATHÉ, J., DE NEEF, P., CNUDDE, J., WAELBROECK, M. & ROBBERECHT, P. (1997c). Development of high affinity selective VIP1 receptor agonists. Peptides, 18, 15391545.
  • GOURLET, P., VERTONGEN, P., VANDERMEERS, A., VANDERMEERS-PIRET, M.C., RATHÉ, J., DE NEEF, P. & ROBBERECHT, P. (1997d). The long-acting vasoactive intestinal polypeptide agonist RO 25–1553 is highly selective of the VIP2 receptor subclass. Peptides, 18, 403408.
  • HARMAR, A.J., ARIMURA, A., GOZES, I., JOURNOT, L., LABURTHE, M., PISEGNA, J.R., RAWLINGS, S.R., ROBBERECHT, P., SAID, S.I., SREEDHARAN, S.P., WANK, S.A. & WASCHEK, J.A. (1998). Nomenclature of receptors for vasoactive intestinal peptide (VIP) and pituitary adenylate cyclase-activating polypeptide (PACAP). Pharmacol. Rev., 50, 265270.
  • JONGSMA, J., OOMEN, M.H., NOORDZIJ, M.A., ROMIJN, J.C., VAN DER KWAST, T.H., SCHRODER, FH & VAN STEENBRUGGE, G.J. (2000). Androgen-independent growth is induced by neuropeptides in human prostate cancer cell lines. Prostate, 42, 3444.
  • JUARRANZ, M.G., BODEGA, G., PRIETO, J.C. & GUIJARRO, L.G. (2001a). Vasoactive intestinal peptide (VIP) stimulates rat prostatic epithelial cell proliferation. Prostate, 47, 285292.
  • JUARRANZ, M.G., BOLAÑOS, O., GUTIÉRREZ-CAÑAS, I., LERNER, E.A., ROBBERECHT, P., CARMENA, M.J., PRIETO, J.C. & RODRIGUEZ-HENCHE, N. (2001b). Neuroendocrine differentiation of the LNCaP prostate cancer cell line maintains the expression and function of VIP and PACAP receptors. Cell. Signall., 13, 887894.
  • JUARRANZ, M.G., DE NEEF, P. & ROBBERECHT, P. (1999). Vasoactive intestinal polypeptide receptor VPAC1 subtype is predominant in rat prostate membranes. Prostate, 41, 16.
  • JUARRANZ, M.G., GUIJARRO, L.G., BAJO, A.M., CARMENA, M.J. & PRIETO, J.C. (1994). Ontogeny of vasoactive intestinal peptide receptors in rat ventral prostate. Gen. Pharmacol., 25, 509514.
  • MARKWALDER, R. & REUBI, J.C. (1999). Gastrin-releasing peptide receptors in the human prostate: relation to neoplastic transformation. Cancer Res., 59, 11521159.
  • MORENO, D., GOURLET, P., DE NEEF, P., CNUDDE, J., WAELBROECK, M. & ROBBERECHT, P. (2000). Development of selective agonists and antagonists for the human vasoactive intestinal polypeptide VPAC2 receptor. Peptides, 21, 15431549.
  • MUNSHI, A., PAPPAS, G., HONDA, T., MCDONNELL, T.J., YOUNES, A., LI, Y. & MEYN, R.E. (2001). TRAIL (APO-2L) induces apoptosis in human prostate cancer cells that is inhibitable by Bcl-2. Oncogene, 20, 37573765.
  • NAGAKAWA, O., OGASAWARA, M., MURATA, J., FUSE, H.C. & SAIKI, I. (2001). Effect of prostatic neuropeptides on migration of prostate cancer cell lines. Int. J. Urol., 8, 6570.
  • PLONOWSKI, A., VARGA, J.L., SCHALLY, A.V., KRUPA, M., GROOT, K. & HALMOS, G. (2002). Inhibition of PC-3 human prostate cancers by analogs of growth hormone-releasing hormone (GH-RH) endowed with vasoactive intestinal peptide (VIP) antagonistic activity. Int. J. Cancer, 98, 624629.
  • PRIETO, J.C. & CARMENA, M.J. (1983). Receptors for vasoactive intestinal peptide on isolated epithelial cell of rat ventral prostate. Biochim. Biophys. Acta, 763, 408413.
  • REUBI, J.C., LÄDERACH, V., WASER, B., GEBBERS, J.O., ROBBERECHT, P. & LAISSUE, J.A. (2000). Vasoactive intestinal peptide/pituitary adenylate cyclase-activating peptide receptor subtypes in human tumours and their tissues of origin. Cancer Res., 60, 31053112.
  • SAID, S.I. (1992). Vasoactive intestinal peptide. Biological role in health and disease. Trends Endocrinol. Metab., 2, 107112.
  • SALIDO, M., VILCHES, J. & LÓPEZ, A. (2000). Neuropeptides bombesin and calcitonin induce resistance to etoposide induced apoptosis in prostate cancer cell lines. Histol. Histopathol., 15, 729738.
  • SALOMON, Y., LONDOS, C. & RODBELL, M. (1974). A highly sensitive adenylate cyclase assay. Anal. Biochem., 58, 541548.
  • SEHGAL, I., POWERS, S., HUNTLEY, B., POWIS, G., PITTELKOW, M. & MAIHLE, N.J. (1994). Neurotensin is an autocrine trophic factor stimulated by androgen withdrawal in human prostate cancer. Proc. Natl. Acad. Sci. U.S.A., 91, 46734677.
  • SHAH, G.V., RAYFORD, W., NOBLE, M.J., AUSTENFELD, M., WEIGEL, J., VAMOS, S. & MEBUST, W.K. (1994). Calcitonin stimulates growth of human prostate cancer cells through receptor-mediated increase in cyclic adenosine 3′,5′- monophosphates and cytoplasmic Ca2+ transients. Endocrinology, 134, 596602.
  • SUMITOMO, M., MILOWSKY, M.I., SHEN, R., NAVARRO, D., DAI, J., ASANO, T., HAYAKAWA, M. & NANUS, DM. (2001). Neutral endopeptidase inhibits neuropeptide-mediated transactivation of the insulin-like growth factor receptor-Akt cell survival pathway. Cancer Res, 61, 32943298.
  • TAINIO, H. (1995). Peptidergic innervation of the human prostate, seminal vesicle and vas deferens. Acta Histochem., 97, 113119.
  • TANG, D.G., LI, L., CHOPRA, D.P. & PORTER, A.T. (1998). Extended survivability of prostate cancer cells in the absence of trophic factors: increased proliferation, evasion of apoptosis, and the role of apoptosis proteins. Cancer Res., 58, 34663479.
  • VAUDRY, D., GONZÁLEZ, B.J., BASILLE, M., YON, L., FOURNIER, A. & VAUDRY, H. (2000). Pituitary adenylate cyclase-activating polypeptide and its receptors: from structure to functions. Pharmacol. Rev., 52, 269324.
  • WONG, H.C., STERNINI, C., LLOYD, K., DE GIORGIO, R. & WALSH, J.H. (1996). Monoclonal antibody to VIP: production, characterization, immunoneutralizing activity, and usefulness in cytochemical staining. Hybridoma, 15, 133139.